Tag: shareholders

FORT WASHINGTON, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL) (TollBrothers.com), the nation's leading builder of luxury homes, today announced that its Board of Directors has approved a quarterly cash dividend to shareholders. The dividend of $0.25 per share will be paid on July 25, 2025 to shareholders of record at the close of business on July 11, 2025.

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced that its board of directors has declared a monthly ordinary dividend of $0.2575 per share of common stock, which is the equivalent of an annualized dividend of $3.09 per share. The dividend is payable in cash on July 15, 2025 to shareholders of record at the close of business on June 30, 2025.

NEW YORK and NEW ORLEANS, June 18, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

JOHANNESBURG, June 18, 2025 (GLOBE NEWSWIRE) -- Renergen is pleased to announce that preferred bidder status has been awarded to He4u consortium for the design, procurement, delivery, construction and commissioning for phase 2 of the Tetra4 LNG and helium liquefaction project, comprising of, Chart Industries Inc. (NYSE: GTLS), Wilson Bayly Holmes - Ovcon Ltd (JSE: WBO), and Aurex Constructors. The appointment of an acceptable EPC contractor in Phase 2 was one of the two remaining conditions for the DFC Phase 2 loan.

DÜSSELDORF, Germany and ATLANTA, June 18, 2025 (GLOBE NEWSWIRE) -- Heramba Electric plc (OTC: PITEF) announced today the results of an extraordinary shareholder and board meeting held on June 3, 2025. More than 90.0%+ of shareholders voted on the following resolutions:

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.